MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

MLTX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

No reported Net Margin figures are available to summarize.

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How MLTX compares with its peers on the latest reported figures

MLTX Competitors Peer median
Net Margin for MLTX and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202642.0% +334.5 pp+152.0 pp
ANABAnaptysBio, Inc.LTM Mar 2026-11.5% +114.2 pp+1245.7 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-1570.9% +793.3 pp-7529.6 pp
ATTOAttovia Therapeutics, Inc.FY2025-4490.9% ——
ALMSAlumis Inc. Common StockLTM Jun 2026-5933.5% -4799.0 pp—
CNTBConnect Biopharma Holdings LimitedFY2025-86687.5% -86627.5 pp—
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ORKAOruka Therapeutics, Inc.FY2025— ——
ZURAZura Bio LimitedFY2025— ——
EQEquillium, Inc.FY2025— ——
Peer median (excluding MLTX) -1570.9%+7.0 pp-192.7 pp

Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.97K0002.62M
Gross Profit(4.97K)000(2.62M)
Gross Margin—————
Research & Development35.52M42.05M31.8M112.77M202.86M
Selling, General & Admin18.05M23.01M22.32M30.32M41.97M
Operating Expenses53.57M65.06M54.12M143.09M242.22M
Depreciation & Amortization4.97K164.78K370.32K1.38M2.62M
EBITDA(53.63M)(64.3M)(43.61M)(119.58M)(219.85M)
EBITDA Margin—————
Operating Income(53.58M)(65.06M)(54.12M)(143.09M)(244.83M)
Operating Margin—————
Interest Income00000
Interest Expense00007.25M
Other Income / Expenses(61.85K)591.73K10.14M22.13M15.12M
Income Before Tax(53.64M)(64.47M)(43.98M)(120.96M)(229.71M)
Pre-Tax Margin—————
Income Tax Expense4.76K36.37K94.39K282.2K611K
Net Income(53.64M)(49.97M)(36.01M)(118.94M)(227.32M)
Net Margin—————
EPS (Basic)(1.45)(2.20)(0.73)(1.89)(3.53)
EPS (Diluted)(1.45)(2.20)(0.73)(1.89)(3.53)
Weighted Avg Shares36.93M29.36M49.12M62.87M64.46M
Weighted Avg Shares (Diluted)36.93M29.36M49.12M62.87M64.46M

MoonLake Immunotherapeutics

NASDAQ:MLTX

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.